We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.24 | -0.26% | 91.66 | 91.64 | 91.66 | 92.24 | 91.57 | 91.83 | 299,123 | 14:10:46 |
From May 2019 to May 2024
By Cecilia Butini
Sanofi SA said Tuesday that it is creating a new company that will focus on active pharmaceutical ingredients and go by the name of Euroapi.
The French pharmaceutical giant said the new company--which will focus on the molecules that give a drug its therapeutic effect--is poised to be the largest European player in the sector. It is expected to generate 1 billion euros ($1.22 billion) in sales by 2022, Sanofi said.
An initial public offering for the company on Euronext Paris will be evaluated for 2022, Sanofi said.
Euroapi's chief executive officer will be Karl Rotthier, effective as of Jan. 18. The company will employ 3,200 skilled employees and will have its headquarters in France, according to Sanofi.
Sanofi's stake in Euroapi will be 30%, said Philippe Luscan, executive vice president of global industrial affairs at the pharmaceutical giant.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
January 12, 2021 09:14 ET (14:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
